NCT02876302: Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

NCT02876302
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Only patients with minimal metastatic disease are eligible; Minimal metastatic disease is defined as evidence of metastatic involvement as demonstrated by imaging only, not amenable to biopsy confirmation; Patients must have the clinical diagnosis of IBC
Exclusions: Patients with known brain metastases
https://ClinicalTrials.gov/show/NCT02876302

Comments are closed.

Up ↑